My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Biotecnología Aplicada
On-line version ISSN 1027-2852
Abstract
ALVAREZ, Eduardo; FAGET, Orestes L; ORLANDI, Neraldo and TORRES, Omaida F. Heberprot-P-associated metabolic control in patients with diabetic foot ulcers. Biotecnol Apl [online]. 2010, vol.27, n.2, pp. 98-100. ISSN 1027-2852.
Diabetes mellitus is a unmet medical need of significant social and economical impact. Diabetic foot is a chronic and avoidable complication, and still the source of non-traumatic amputations, with metabolic imbalance, macroand micro-angiopathy, and ulceration or trauma contributing to its development. The introduction of Heberprot-P to treat diabetic foot ulcers has been a tremendous advance to reduce the amputation index and disability among patients. However, it is essential to guarantee an optimal and personalized glycemic control for achieving even more favorable results. This can be attained by implementing an intensive therapeutic strategy with multiple doses of insulin since the very first diagnose of the lesion. Due to the relevance of this topic for medical practice, here is reviewed how to establish such a therapy, and the goals for glycemic control to achieve a better quality of life when attending diabetic foot ulcer patients.
Keywords : Diabetes mellitus; diabetic foot; glycemic control; metabolic control; Heberprot-P.